AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news